Overview

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.

Full Product Details

Author:   Mark A. Geyer ,  Gerhard Gross
Publisher:   Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
Imprint:   Springer-Verlag Berlin and Heidelberg GmbH & Co. K
Edition:   2012 ed.
Volume:   213
Dimensions:   Width: 15.50cm , Height: 2.40cm , Length: 23.50cm
Weight:   0.712kg
ISBN:  

9783642438097

ISBN 10:   3642438091
Pages:   458
Publication Date:   09 November 2014
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Preface.- Clinical instruments to evaluate and guide treatment in schizophrenia.- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders.- Nicotinic mechanisms in psychotic disorders.- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia.- Inhibitors of glycine transport as potential new treatments in schizophrenia.- The role of glutamate in schizophrenia.- Metabotropic glutamate receptors as targets for new treatments in schizophrenia.- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions.- Phosphodiesterase inhibitors as potential new treatments in schizophrenia.- Disease modifying approaches to schizophrenia.- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia.- Transgenic animals reflecting aspects of schizophrenia.- Behavioral animal models of pro-cognitive treatments for schizophrenia. 

Reviews

From the reviews: The target audience ... is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. ... This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a 'one disease' perspective. (Michael Joel Schrift, Doody's Book Reviews, March, 2013)

From the reviews: The target audience ... is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. ... This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a `one disease' perspective. (Michael Joel Schrift, Doody's Book Reviews, March, 2013)

From the reviews: The target audience is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a one disease perspective. (Michael Joel Schrift, Doody's Book Reviews, March, 2013)

Author Information

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions